NO20041452L - 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer. - Google Patents

17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.

Info

Publication number
NO20041452L
NO20041452L NO20041452A NO20041452A NO20041452L NO 20041452 L NO20041452 L NO 20041452L NO 20041452 A NO20041452 A NO 20041452A NO 20041452 A NO20041452 A NO 20041452A NO 20041452 L NO20041452 L NO 20041452L
Authority
NO
Norway
Prior art keywords
androgen
inhibitors
beta
treatment
hydroxysteroid dehydrogenase
Prior art date
Application number
NO20041452A
Other languages
English (en)
Other versions
NO327254B1 (no
Inventor
Viyyoor Moopil Girijavallabhan
Anil K Saksena
Yi-Tsung Liu
Timothy J Guzi
Ronald J Doll
Jonathan A Pachter
Alan K Mallams
Kamil Paruch
Jocelyn D Rivera
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20041452L publication Critical patent/NO20041452L/no
Publication of NO327254B1 publication Critical patent/NO327254B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20041452A 2001-09-06 2004-04-05 3-17-beta-hydroksysteroiddehydrogenaseinhibitorforbindelser, farmasoytiske preparater og anvendelse av forbindelsene ved fremstilling av en medisin for behandling eller profylakse av androgenavhengige sykdommer. NO327254B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31771501P 2001-09-06 2001-09-06
PCT/US2002/028181 WO2003022835A1 (en) 2001-09-06 2002-09-05 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Publications (2)

Publication Number Publication Date
NO20041452L true NO20041452L (no) 2004-06-04
NO327254B1 NO327254B1 (no) 2009-05-25

Family

ID=23234950

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041452A NO327254B1 (no) 2001-09-06 2004-04-05 3-17-beta-hydroksysteroiddehydrogenaseinhibitorforbindelser, farmasoytiske preparater og anvendelse av forbindelsene ved fremstilling av en medisin for behandling eller profylakse av androgenavhengige sykdommer.

Country Status (30)

Country Link
US (3) US6903102B2 (no)
EP (1) EP1423381B1 (no)
JP (1) JP4320252B2 (no)
KR (1) KR100991616B1 (no)
CN (1) CN1551878B (no)
AR (1) AR036492A1 (no)
AT (1) ATE350375T1 (no)
AU (1) AU2002326823B2 (no)
BR (1) BR0212378A (no)
CA (1) CA2459311C (no)
CY (1) CY1106521T1 (no)
DE (1) DE60217363T2 (no)
DK (1) DK1423381T3 (no)
EC (1) ECSP045004A (no)
ES (1) ES2276950T3 (no)
HK (1) HK1062677A1 (no)
HU (1) HUP0402629A3 (no)
IL (2) IL160065A0 (no)
MX (1) MXPA04002167A (no)
MY (1) MY141661A (no)
NO (1) NO327254B1 (no)
NZ (1) NZ530810A (no)
PE (1) PE20030703A1 (no)
PL (1) PL369108A1 (no)
PT (1) PT1423381E (no)
RU (1) RU2315763C2 (no)
SI (1) SI1423381T1 (no)
TW (1) TWI329108B (no)
WO (1) WO2003022835A1 (no)
ZA (1) ZA200401456B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
EP1436281B1 (en) * 2001-10-17 2010-06-16 Schering Corporation Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
DE60332862D1 (de) 2002-11-18 2010-07-15 Schering Corp 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
DE60323765D1 (de) 2002-12-17 2008-11-06 Schering Corp Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
TW200528110A (en) * 2003-12-17 2005-09-01 Schering Corp Pharmaceutical compositions
KR101536701B1 (ko) 2004-01-07 2015-07-14 앙도르쉐르슈 인코포레이티드 헬릭스 12 배향형 스테로이드계 약학 제품
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7138246B2 (en) * 2004-03-01 2006-11-21 Bristol-Myers Squibb Company Methods for identifying or screening for agents that modulate 17β-HSD3
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7569725B2 (en) 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US8884061B2 (en) * 2006-03-03 2014-11-11 Colorado State University Research Foundation Compositions and methods of use of electron transport system inhibitors
AU2007244960B2 (en) * 2006-04-24 2012-03-01 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL2049475T3 (pl) * 2006-04-24 2012-08-31 Lilly Co Eli Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1
MY153714A (en) * 2006-06-28 2015-03-13 Amgen Inc Glycine transporter-1 inhibitors
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
EP2119709A4 (en) * 2007-02-09 2011-08-17 Kaneka Corp PROCESS FOR PREPARING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
EP2744808A4 (en) 2011-08-16 2015-04-01 Sinai School Medicine TRICYCLIC COMPOUNDS AS ACTIVE AGENTS AGAINST CANCER
WO2014134169A1 (en) * 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
WO2014207309A1 (en) 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1
WO2014207311A1 (en) 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1
SG11201510251TA (en) 2013-06-25 2016-01-28 Forendo Pharma Ltd Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
KR20160042089A (ko) * 2013-09-12 2016-04-18 화이자 인코포레이티드 심상성 여드름 치료용 아세틸-CoA 카복실라아제 억제제의 용도
CN103755626A (zh) * 2014-01-23 2014-04-30 安徽安腾药业有限责任公司 一种贝托斯汀关键中间体的合成方法
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP6545266B2 (ja) 2014-12-23 2019-07-17 フォレンド ファーマ リミテッド １７β‐ＨＳＤ１抑制剤のプロドラッグ
JP6523461B2 (ja) 2014-12-23 2019-06-05 フォレンド ファーマ リミテッド １７β−ＨＳＤ１−阻害剤のプロドラッグ
WO2018202487A1 (en) 2017-05-04 2018-11-08 Basf Se Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for combating phytopathogenic fungi
CN115716860A (zh) 2017-06-08 2023-02-28 佛恩多制药有限公司 15β-[3-丙酰氨基]-取代的雌-1,3,5(10)-三烯-17-酮及17-肟
KR20210114390A (ko) 2018-12-05 2021-09-23 포렌도 파마 리미티드 17-hsd1의 억제제로서의 피라졸 고리와 위치 16(17)에서 축합된 에스트라-1,3,5(10)-트리엔 화합물
US11957687B2 (en) 2019-07-02 2024-04-16 Regeneron Pharmaceuticals, Inc. Modulators of HSD17B13 and methods of use thereof
WO2021037750A1 (en) 2019-08-28 2021-03-04 Unilever Global Ip Limited Novel compounds for skin lightening

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594309B2 (en) 1984-08-02 1990-03-08 Fernand Labrie Pharmaceutical composition for combination therapy of hormonedependent cancers
ES2077675T3 (es) 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
CA2062792C (en) 1989-07-07 2006-03-21 Fernard Labrie Treatment of androgen-related diseases
KR920703063A (ko) 1989-07-07 1992-12-17 원본미기재 양성 전립선 비대증의 예방 및/ 또는 치료를 위한 복합요법
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
CZ280532B6 (cs) * 1990-10-10 1996-02-14 Schering Corporation Pyridinové a pyridin-N-oxidové deriváty diaryl-methyl-piperidinů nebo piperazinů, jejich použití a způsob jejich přípravy, farmaceutický prostředek je obsahující
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
JPH07505393A (ja) 1992-03-27 1995-06-15 シェリング・コーポレーション 非橋渡しビスアリールカルビノール誘導体，組成物および使用法
WO1994026767A1 (en) 1993-05-17 1994-11-24 Endorecherche Inc. Improved antiandrogens
WO1994010165A1 (en) 1992-10-28 1994-05-11 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
CA2150951A1 (en) 1992-12-14 1994-06-23 Angus Murray Macleod 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
AU680020B2 (en) 1993-06-07 1997-07-17 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
DE69504300T2 (de) 1994-01-13 1999-04-29 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin-antagonisten
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5688960A (en) 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
US5789422A (en) 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5945428A (en) 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5783579A (en) 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
US6673799B1 (en) 1998-09-22 2004-01-06 Yamanouchi Pharmaceutical Co. Ltd. Cyanophenyl derivative
US6063926A (en) 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
US6204265B1 (en) 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
WO2000043008A1 (en) 1999-01-25 2000-07-27 Smithkline Beecham Corporation Anti-androgens and methods for treating disease
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
KR20020073586A (ko) * 2000-02-11 2002-09-27 버텍스 파마슈티칼스 인코포레이티드 피페라진 및 피페리딘 유도체

Also Published As

Publication number Publication date
EP1423381A1 (en) 2004-06-02
BR0212378A (pt) 2004-10-19
RU2004110410A (ru) 2005-10-20
DE60217363T2 (de) 2007-10-11
DK1423381T3 (da) 2007-05-07
HK1062677A1 (en) 2004-11-19
EP1423381B1 (en) 2007-01-03
SI1423381T1 (sl) 2007-04-30
JP2005502705A (ja) 2005-01-27
IL160065A0 (en) 2004-06-20
NZ530810A (en) 2006-05-26
ATE350375T1 (de) 2007-01-15
US6903102B2 (en) 2005-06-07
KR20040031042A (ko) 2004-04-09
HUP0402629A3 (en) 2009-09-28
US7138396B2 (en) 2006-11-21
MXPA04002167A (es) 2004-06-29
US20060069103A1 (en) 2006-03-30
CA2459311A1 (en) 2003-03-20
AU2002326823B2 (en) 2005-12-15
PL369108A1 (en) 2005-04-18
CY1106521T1 (el) 2012-01-25
US20040132736A1 (en) 2004-07-08
WO2003022835A1 (en) 2003-03-20
IL160065A (en) 2009-07-20
PE20030703A1 (es) 2003-08-21
RU2315763C2 (ru) 2008-01-27
ZA200401456B (en) 2004-10-19
ECSP045004A (es) 2004-04-28
US20060014755A1 (en) 2006-01-19
MY141661A (en) 2010-05-31
CN1551878A (zh) 2004-12-01
US7432268B2 (en) 2008-10-07
ES2276950T3 (es) 2007-07-01
NO327254B1 (no) 2009-05-25
CN1551878B (zh) 2011-08-10
CA2459311C (en) 2010-08-03
TWI329108B (en) 2010-08-21
HUP0402629A2 (hu) 2005-05-30
DE60217363D1 (de) 2007-02-15
PT1423381E (pt) 2007-04-30
KR100991616B1 (ko) 2010-11-04
JP4320252B2 (ja) 2009-08-26
AR036492A1 (es) 2004-09-15

Similar Documents

Publication Publication Date Title
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
NO20052058D0 (no) Behandling av influensa.
NO20053041D0 (no) Behandling av diabetes.
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20033594D0 (no) Fenetanolamin-derivater for behandling av luftveissykdommer
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
NO20052469D0 (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
CY2014019I1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20035522D0 (no) Kinuklidin-substituerte multisykliske heteroaryler for behandling av sykdom
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60308431D1 (de) Geschäumte Säurebehandlungsflüssigkeit
NO20045554L (no) Fremgangsmate for behandling av diabetes
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
NO20052471D0 (no) Fremgangsmate for fremstilling av 3-metyltiopropanal.
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
NO20033804L (no) Karbamatforbindelser for behandling av smerte
FI20012170A0 (fi) Menetelmä lauhteiden käsittelemiseksi
NO20042904L (no) Anvendelse av norepinefrin-reopptakinhibitorer for behandling av kognitiv svikt

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees